Clinical Trials Logo

Hepatitis clinical trials

View clinical trials related to Hepatitis.

Filter by:

NCT ID: NCT00148863 Completed - Clinical trials for Hepatitis C, Chronic

Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C

Start date: June 2004
Phase: Phase 2
Study type: Interventional

Viral hepatitis C is treated with peg-interferon alpha 2a/2b and ribavirin. There is no treatment recommended for non responders patients. This study will evaluate the efficacy, after a second treatment with peg-interferon alpha 2a and ribavirin for 12 Weeks of the addition of interferon gamma in non responders patients

NCT ID: NCT00148031 Completed - Hepatitis C Clinical Trials

Improving Hepatitis C Treatment in Injection Drug Users

Start date: September 2003
Phase: Phase 4
Study type: Interventional

The overall goal of the research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection. Hypothesis: An intervention designed to improve the rate of HCV treatment completion and sustained virologic response (SVR) in IDUs will increase access by integrating HCV medical care into a substance abuse treatment program.

NCT ID: NCT00147784 Completed - Opiate Dependence Clinical Trials

HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.

Start date: March 2006
Phase: Phase 3
Study type: Interventional

- To evaluate if weekly psychological follow-up make opioid dependent patients in MMT able to accomplish 14 weeks treatment with Peginterferon alfa-2a (PEG-INF) and ribavirin to the same extent than non-opioid dependents. - To determine the efficacy of this anti-HCV treatment

NCT ID: NCT00146016 Completed - Chronic Hepatitis C Clinical Trials

Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients

Start date: February 2000
Phase: Phase 3
Study type: Interventional

* Adding Amantadine to standard anti-viral treatment can improve sustained response rates in patients with chronic hepatitis C

NCT ID: NCT00144469 Completed - Chronic Hepatitis C Clinical Trials

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C

Start date: May 2002
Phase: Phase 3
Study type: Interventional

This study evaluated the efficacy and safety of the combination of peginterferon alfa-2a plus ribavirin in treatment-naïve patients with HCV genotype 1b infection, compared with peginterferon alfa-2a monotherapy. Additionally, the study evaluated the efficacy and safety of the combination of peginterferon alfa-2a plus ribavirin in patients with CHC who had failed to respond to previous conventional-interferon based therapy.

NCT ID: NCT00144313 Completed - Hepatitis Clinical Trials

VaxTeen Hepatitis B Vaccine Booster Study

Start date: August 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine immune status of adolescents who responded to a primary series of recombinant hepatitis B vaccine given at birth and to assess their response to a booster dose of vaccine.

NCT ID: NCT00143000 Completed - Hepatitis C Virus Clinical Trials

Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3

Start date: April 2004
Phase: Phase 4
Study type: Interventional

The primary objective of the study is to demonstrate that the efficacy of peginterferon alfa-2a 40KD combination therapy with ribavirin in interferon naïve patients with chronic hepatitis C virus infection genotype 2 or 3 given for 12 weeks is non-inferior to 24 weeks.

NCT ID: NCT00142740 Completed - HIV Infection Clinical Trials

Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025

Start date: October 2005
Phase: N/A
Study type: Observational

This laboratory-based substudy of an effectiveness trial of two Hepatitis B vaccines in HIV-negative youths is being done to evaluate the genetic contribution to the individualized immune response.

NCT ID: NCT00142298 Completed - Chronic Hepatitis B Clinical Trials

Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies

Start date: March 2005
Phase: Phase 3
Study type: Interventional

This trial is being conducted as an open-label, extended-term study for patients with chronic hepatitis B who have previously completed an Idenix-sponsored trial with telbivudine.

NCT ID: NCT00142103 Completed - Clinical trials for Hepatitis, Chronic Active

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects

Start date: September 2005
Phase: Phase 1
Study type: Interventional

1. To characterize the tolerability profile of subcutaneous (SC) CPG 10101 alone, with pegylated interferon, ribavirin or both pegylated interferon and ribavirin when administered weekly for twelve weeks in relapsed HCV positive subjects. 2. To assess the effect of subcutaneous (SC) CPG 10101 alone, with pegylated interferon, ribavirin or both pegylated interferon and ribavirin on serum Hepatitis C Virus (HCV) RNA concentrations